Halozyme Therapeutics | HALO - Current Liabilities



Halozyme Therapeutics reported $134.28M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
Agios Pharmaceuticals USD 70.41M 18.04M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Amarin USD 162.41M 17.54M Mar/2025
Amgen USD 20.48B 2.53B Jun/2025
Baxter International USD 3.48B 3.03B Mar/2025
Cytokinetics USD 131.06M 28.66M Jun/2025
DBV Technologies USD 49.42M 9.04M Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Halozyme Therapeutics USD 134.28M 16.1M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
MannKind USD 111.83M 4.11M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
United Therapeutics USD 527.1M 194.4M Jun/2025